ASSEMBLY BIOSCIENCES, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $72.3M | $28.5M | $7.2M | $0 | $6.3M |
| Research and development | $64.8M | $55.9M | $48.9M | $70.0M | $68.5M |
| Operating expenses | $84.4M | $73.9M | $71.8M | $94.1M | $138.9M |
| Operating income | -$12.1M | -$45.4M | -$64.6M | -$94.1M | -$132.7M |
| Pretax income | -$6.1M | -$39.8M | -$61.2M | -$93.1M | -$132.4M |
| Income tax expense | $0 | $330,000 | $33,000 | $0 | -$2.5M |
| Net income | -$6.1M | -$40.2M | -$61.2M | -$93.1M | -$129.9M |
| Balance Sheet | |||||
| Cash and equivalents | $58.5M | $38.3M | $19.8M | $52.4M | $45.6M |
| Current assets | $254.5M | $115.5M | $133.8M | $97.0M | $154.2M |
| Total assets | $257.6M | $119.2M | $136.8M | $101.8M | $191.1M |
| Current liabilities | $48.8M | $47.8M | $39.2M | $16.3M | $16.1M |
| Total liabilities | $50.8M | $85.8M | $95.7M | $19.1M | $22.1M |
| Stockholders' equity | $206.8M | $33.4M | $41.1M | $82.7M | $168.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$41.1M | -$51.1M | $22.7M | -$84.5M | -$93.4M |
| Depreciation and amortization | $129,000 | $129,000 | $450,000 | $498,000 | $466,000 |
| Stock-based compensation | $4.7M | $3.1M | $5.1M | $6.6M | $5.2M |
| Capital expenditure | $66,000 | $28,000 | $255,000 | $102,000 | $3.1M |
| Free cash flow | -$41.2M | -$51.1M | $22.5M | -$84.6M | -$96.5M |
| Impairments | — | — | — | — | $12.6M |
Shares outstanding 15.9M · Free float 16.7%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.